Little Green Pharma Enters Into Agreement to Supply Medicinal Cannabis Products to DEMECAN

Highlights:

• Little Green Pharma signs three-year purchase agreement with Berlin-based DEMECAN for the sale and export of up to 1,000kg of dried flower or 48,000 units of medicinal cannabis oil product, or any combination thereof, per annum
• DEMECAN is the only German company that covers the entire medicinal cannabis production chain; from cultivation to processing and manufacturing, through to distribution to pharmacies
• LGP anticipates being one of the first few companies to export full spectrum medicinal cannabis oil products into Germany
• The German market is the largest medicinal cannabis market in the European Union with an estimated 240,000 prescriptions to the end of 20191
• It is expected Germany will remain a favourable market for the import of medicinal cannabis oil products due to insufficient domestic supply as a result of significant delays in its domestic cultivation tendering process

MONTREAL, Feb. 27, 2020 (GLOBE NEWSWIRE) -- ELIXXER, LTD. (TSX-V: ELXR.  OTCQB: ELIXF) (“ELXR” or the “Company”) is pleased to announce that Little Green Pharma (ASX: LGP) has signed a binding three-year purchase agreement (“Agreement”) for the sale, export, and distribution of LGP Classic medicinal cannabis oils and LGP-cultivated dried cannabis flower to Berlin-based Deutsche Medizinalcannabis GmbH (“DEMECAN”).

DEMECAN is the only German company that covers the entire medicinal cannabis production chain; from cultivation to processing and manufacturing, through to distribution to pharmacies. DEMECAN is currently the only producer of medicinal cannabis in Germany and is a strategically important partner for LGP.

The Agreement does not require DEMECAN to purchase a minimum volume. Subject to the conditions precedent and material terms of the Agreement, as set out below, LGP will sell and export to DEMECAN up to 1,000kg of LGP-cultivated dried cannabis flower or 48,000 units of LGP Classic medicinal cannabis oil product, or any combination thereof, per annum (the “Annual Quota”). The Agreement has a three-year term, which will commence on the first commercial shipment of LGP medicinal cannabis products to Germany, which is expected to take place in the second half of 2020.